Sloan-kettering Institute for Cancer Research

Memorial Sloan Kettering Cancer Center

Aragon Pharmaceuticals, Inc.

The Rockefeller University

Albert Einstein College of Medicine

Ouathek Ouerfelli

Anna Dilhas

Nicholas D Smith

Mark R Herbert

Guangbin Yang

Hong Zhao

Guangli Yang

Samuel J Danishefsky

Marilyn D Resh

Elissaveta Petrova

Joseph Fraser Glickman

Joan Massague

Warren D W Heston

Sarah M Cheal

Emily H Cheng

James Hsieh

John Pinto

Anna Dihas

Nicolas Lecomte

Thordur Oskarsson

Paul Jeng

Manuel Valiente Cortes

Scott D Kuduk

Steven M Larson

Evripidis Gavathiotis

Michael R McDevitt

Neal Rosen

Malcolm A Moore

Laura Sepp-Lorenzino

William R Fair

Ron S Israeli

Steve Larson

Isabelle Riviere

Xiuyan Wang

Malcom Moore

Frances Weis-Garcia

Malcolm Moore

Michael Mcdevitt

Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.

Crystalline forms of an androgen receptor modulator

Provided herein are anti-CD20 antibodies and uses thereof for treatment and diagnosis. Also provided are CD20 antigens for the production of anti-CD20 antibodies and methods of generating anti-CD20 antibodies using the CD20 antigens.

Anti-CD20 antibody and uses thereof

The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g.,Ac). Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.

Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy

The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy.

N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy

Described herein are phenylsulfonamido-benzofuran derivatives, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, methods, uses, and kits involving compounds of Formulae (I), (II), (III), (IV), (V), or (VI) for treating and/or preventing proliferative diseases (e.g. cancers, inflammatory diseases, and autoimmune diseases) in a subject. The compounds and pharmaceutical compositions as described herein inhibit at least one protein of the BCL-2 family in a biological sample or subject to treat and/or prevent a proliferative disease. In certain embodiments, compounds described herein are selective inhibitors of MCL-1, a BCL-2 family member protein. 

Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.

Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed. The method involves exposing the cells to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines of formula I 

Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines

A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52.

Synthesis of thiohydantoins

Treatment of pancreatic and related cancers with 5-acyl-6,7-Dihydrothieno[3,2-C]pyridines

Growing community of inventors

Fort Lee, NJ, United States of America

Ouathek Ouerfelli